RS 100329

an alpha(1A)-adrenoceptor antagonist; structure in first source

Also Known As:

5-Methyl-3-(3-(4-(2-(2,2,2-trifluoroethoxy)phenyl)-1-piperazinyl)propyl)-2,4(1H,3H)-pyrimidinedione; RS-100329; RS100329

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 05/01/1999 - "The alpha1A-AR subtype selectivity of Ro 70-0004 and RS-100329, demonstrated in both cloned and native systems, should allow for an evaluation of the clinical utility of a 'uroselective' agent for the treatment of symptoms associated with benign prostatic hyperplasia."
2.	Hypothermia 02/01/2008 - "The alpha(1A)-adrenoceptor antagonist RS 100329 (0.1 mg kg(-1)), or the alpha(1D)-adrenoceptor antagonist BMY 7378 (0.5 mg kg(-1)) given alone, did not reveal a hypothermia to MDMA, but the combination of the two antagonists revealed a significant hypothermia to MDMA. "
3.	Hyperplasia 02/15/2003 - "Only the alpha(1A)-adrenoceptor selective subtype antagonist RS100329 abrogated the phenylephrine-induced hyperplasia. "

1.	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)
2.	Phenylephrine (Neo-Synephrine)
3.	Ro 70-0004
4.	BMY 7378